do want to shift gears here though and move into talking about Chinese tech stocks and some opportunities in China. Welcome in our next guest, bring Sam back into the conversation. Joining us now, Henry Green, senior investment strategist at Crane Shares.Henry, great to have you with us. So, we've seen how this AI tech theme is playing out in US markets. How is it playing out in China. Is it similar. Is it different.What are you seeing. >> Sure. Uh, thanks for having me.Yeah, I think it is different than in ...

the section of the the investor base that basically thinks Netflix should walk away look at the regulatory road ahead. They look at the integration risk and then like what Netflix is a big global technology company as opposed to being something sort of micro focused on Hollywood, >> right. And and so so so answer those those investors, right.You know, why why are they wrong that actually there is a longer list of reasons to walk away than stick with it at this juncture. Well, this this deal offers great val ...

Core Insights - Elon Musk's merger of SpaceX and xAI has created a combined entity valued at $1.25 trillion, significantly increasing Musk's net worth to approximately $845 billion [1][2] - The merger indicates a strategic shift in Musk's financial focus from Tesla to SpaceX, which now represents nearly two-thirds of his wealth [2][3] - Musk's ownership in the new entity is estimated at around 43%, valued at over $530 billion, reflecting a rapid transformation in his financial landscape [3] Financial Implications - For Musk to achieve trillionaire status, SpaceX would need to reach a valuation of approximately $1.6 trillion, assuming Tesla's stock price remains stable [5] - SpaceX's merger with xAI is viewed as a strategic move to access larger capital markets, particularly for funding AI model development [4] Market Dynamics - Musk's shift in focus towards SpaceX is driven by lucrative contracts with the federal government, valued at over $20 billion, amidst declining brand value and core sales for Tesla [7] - The merger has sparked discussions about Musk's ambitions in the aerospace and AI sectors, highlighting the potential for growth in these industries [2][4]

The US Treasury Department has requested information from Adani Enterprises related to allegations in a news report that the company imported Iranian oil products into India https://t.co/1C71Th9il5 ...

Core Viewpoint - Paramount Skydance has initiated "Plan D" to challenge Netflix's bid for Warner Bros. Discovery, emphasizing the regulatory uncertainties surrounding the Netflix deal and its potential implications for both the transaction and Netflix itself [1][6]. Group 1: Plans and Strategies - "Plan A" involved a $30-a-share all-cash offer from Paramount for Warner Bros. Discovery, which was deemed superior to Netflix's $27.75 cash-and-stock proposal [2]. - "Plan B" was a hostile bid aimed at persuading WBD shareholders to accept Paramount's cash offer [4]. - "Plan C" included the possibility of litigation against WBD for allegedly favoring Netflix's bid due to personal connections between executives [5]. Group 2: Financial Implications - The Netflix deal is under scrutiny as it promises shareholders a seemingly unrealistic $3 per share from the sale of WBD's cable properties, which may not materialize [4]. - Paramount argues that WBD's cable spinoff, burdened with $15 billion in debt, may only yield minimal returns for investors [11]. - Netflix has lost $160 billion in market capitalization since its one-year high in June, raising concerns about its ability to afford the deal amidst $60 billion in debt [7]. Group 3: Regulatory Concerns - The merger between Netflix and WBD is expected to face significant regulatory scrutiny, particularly from the Trump administration, which could complicate the approval process [12][16]. - There are indications that Netflix's business model may be reviewed for potential monopoly status, similar to the scrutiny faced by Amazon and Google [17]. - The regulatory environment is becoming increasingly challenging, with discussions in Washington about Netflix's market dominance [17]. Group 4: Future Considerations - WBD is reportedly interested in a "Plan E," which would involve the Ellisons and Cardinale increasing their offer [18]. - The emergence of "Plan D" suggests that Paramount may consider stepping back if regulatory challenges persist, potentially leaving the deal vulnerable [18].

Core Viewpoint - Merck & Co., Inc. is set to report its fiscal fourth-quarter earnings for 2025, with analysts projecting a significant increase in earnings per share (EPS) compared to the previous year [1][2]. Financial Performance - Analysts expect Merck to report a profit of $2.08 per share on a diluted basis for Q4 2025, reflecting a 20.9% increase from $1.72 per share in the same quarter last year [2]. - For the full year, the expected EPS is $8.99, which is a 17.5% increase from $7.65 in fiscal 2024, but a decline of 6.8% is anticipated for fiscal 2026, bringing the EPS down to $8.38 [3]. Stock Performance - Over the past 52 weeks, Merck's stock has increased by 8.4%, underperforming the S&P 500 Index's 16.2% gains and the Health Care Select Sector SPDR Fund's 11.6% returns [4]. - The stock's underperformance is attributed to regulatory scrutiny, pricing pressures, and patent expirations for key drugs, alongside slowing growth in Keytruda and declining sales of Winrevair and Gardasil in China [5]. Recent Earnings Report - On October 30, 2025, Merck reported an adjusted EPS of $2.58, exceeding Wall Street's expectations of $2.36, with revenue reaching $17.3 billion, surpassing forecasts of $17.1 billion [6]. - The company anticipates full-year adjusted EPS between $8.93 and $8.98, with revenue expected to be in the range of $64.5 billion to $65 billion [6]. Analyst Ratings - The consensus opinion on Merck stock is moderately bullish, with a "Moderate Buy" rating. Out of 26 analysts, 14 recommend a "Strong Buy," one suggests a "Moderate Buy," and 11 give a "Hold" rating [7]. - The average analyst price target for Merck is $111.35, indicating a potential upside of 3.6% from current levels [7].

Core Insights - The "Buy Now, Pay Later" (BNPL) services are becoming increasingly popular during the holiday shopping season, with spending expected to reach $20.2 billion, an 11% increase from the previous year [2] - Annual BNPL spending is projected to hit $116.7 billion by 2025, doubling from 2022 and increasing more than sevenfold compared to 2020 [3] - A survey indicates that half of holiday shoppers are likely to use BNPL services if available, highlighting its growing acceptance [4] Industry Trends - BNPL services are embedded in consumer culture, leading to higher average order values—91% for enterprises and 62% for small businesses [5] - Despite the growth, there are rising concerns about the financial strain on consumers, with 41% of users admitting to missing payments, up from 34% last year [6] - Financial experts warn that BNPL can create a false sense of affordability, leading consumers to make purchases beyond their means [7] Regulatory Environment - There is increasing regulatory scrutiny on BNPL services, with proposed legislation aimed at extending consumer protections similar to those for credit cards [10] - A multistate inquiry into major BNPL providers is underway, focusing on fees, disclosures, and consumer risks [11] - The regulatory landscape is inconsistent, with BNPL products being treated differently across states, leading to confusion and potential regulatory arbitrage [12] Market Performance - The year 2025 has been mixed for BNPL companies, with varying stock performances: PayPal down 30.54%, Block down 24.90%, Affirm up 25.69%, Klarna down 31.67%, Sezzle up 65.27%, and Zip up 7.32% [15]

Core Viewpoint - Paramount Skydance is aggressively pursuing an acquisition of Warner Bros Discovery (WBD) through a hostile bid, despite Netflix's agreement to acquire WBD's studio and streaming operations for $27.75 per share [1][2]. Group 1: Paramount's Offer - Paramount's all-cash tender offer is for $30 per share, valuing the entire company at $108.4 billion, which represents a significant premium over the current stock price [2]. - Paramount argues that its acquisition proposal offers better value for shareholders and is more likely to pass regulatory scrutiny compared to Netflix's deal [3][4]. Group 2: Shareholder Communication - David Ellison emphasized that WBD shareholders should consider Paramount's superior all-cash offer, which he claims provides a more certain and quicker path to completion [5]. - Paramount has expressed concerns that WBD is not fairly considering its offers and has accused the company of favoring a single bidder [5]. Group 3: Employee Sentiment - Employees at CNN expressed relief over Netflix's acquisition, fearing a merger with CBS News, which could lead to job losses [6][8]. - However, Paramount's offer could reignite concerns among employees at both networks regarding job security if the acquisition proceeds [9]. Group 4: Regulatory Considerations - Donald Trump indicated he would be involved in reviewing the Netflix-WBD transaction, citing competition concerns due to Netflix's market share [10]. - Paramount is confident that its proposed acquisition will not face Federal Communications Commission review, as no television licenses would be transferred, but it will be subject to Department of Justice anti-trust review [11][12].

Core Viewpoint - Hagens Berman has initiated an investigation into StubHub Holdings, Inc. regarding the accuracy of statements made in its IPO documents, particularly concerning market opportunities and regulatory exposure to the U.K.'s Competition and Markets Authority (CMA) [1][6]. Group 1: IPO and Growth Projections - StubHub's IPO materials highlighted a significant growth opportunity in the secondary ticketing sector, claiming that "Growth and Liquidity Flywheels" were crucial for establishing its leadership in the global market [2]. - The investment thesis presented to the market was heavily reliant on these optimistic projections [2]. Group 2: Market Reaction and Share Price Decline - Following the close of business on November 13, 2025, StubHub's share price dropped approximately 20% in the next trading session due to investor disappointment [3]. - On November 18, 2025, a regulatory announcement further impacted investor confidence, leading to an additional 9% decline in StubHub's stock price [5]. Group 3: Regulatory Investigation - The U.K.'s CMA has opened an investigation into StubHub, focusing on price transparency and the mandatory additional charges applied when consumers purchase tickets [8]. - This investigation is part of a broader review of over 400 businesses across 19 sectors to assess compliance with price transparency regulations [8]. Group 4: Financial Performance and Management Response - StubHub's Q3 2025 financial results were released without guidance for Q4 2025, with the CFO indicating that 2025 was expected to be a more challenging growth environment [7]. - The investigation by Hagens Berman is centered on whether misleading statements were made regarding growth prospects and regulatory risks [6][7].

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between January 8, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential financial harm [3] Case Details - The lawsuit outlines that DexCom's design changes to the G6 and G7 were not authorized by the U.S. Food and Drug Administration [3] - It is alleged that these changes compromised the accuracy of glucose readings, which is critical for users relying on these devices for health management [3] - The complaint indicates that the public statements made by the defendants were materially false and misleading throughout the relevant period [3] Next Steps - Shareholders who suffered losses in DexCom stock during the specified timeframe are encouraged to seek information about their rights to recovery [4] - Participation in the recovery process is stated to be at no cost or obligation to the shareholders [4] Firm Background - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5] - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5] - Levi & Korsinsky has extensive experience in complex securities litigation, with a dedicated team to support clients [5]